Evogene Financial Statements From 2010 to 2024

EVGN Stock  USD 1.67  0.05  3.09%   
Evogene financial statements provide useful quarterly and yearly information to potential Evogene investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Evogene financial statements helps investors assess Evogene's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Evogene's valuation are summarized below:
Gross Profit
766 K
Profit Margin
(2.10)
Market Capitalization
M
Enterprise Value Revenue
0.4902
Revenue
9.4 M
We have found one hundred twenty available fundamental signals for Evogene, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Evogene's prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 26th of November 2024, Market Cap is likely to drop to about 358 M. In addition to that, Enterprise Value is likely to drop to about 349.2 M

Evogene Total Revenue

5.96 Million

Check Evogene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evogene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 M, Interest Expense of 162.4 K or Selling General Administrative of 5.2 M, as well as many indicators such as Price To Sales Ratio of 63.47, Dividend Yield of 0.0 or PTB Ratio of 29.7. Evogene financial statements analysis is a perfect complement when working with Evogene Valuation or Volatility modules.
  
Check out the analysis of Evogene Correlation against competitors.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

Evogene Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets65 M51.1 M80.1 M
Slightly volatile
Common Stock Shares Outstanding4.3 M4.6 M17.8 M
Slightly volatile
Other Current Liabilities2.8 M3.6 M2.9 M
Very volatile
Total Current Liabilities5.6 M6.9 MM
Slightly volatile
Total Stockholder Equity11.5 M12.1 M59.8 M
Slightly volatile
Other Liabilities17.8 M17 M7.4 M
Slightly volatile
Accounts Payable1.2 M1.8 M1.5 M
Slightly volatile
Cash26.8 M20.8 M23.4 M
Pretty Stable
Other Assets0.951.031.5 K
Very volatile
Short Term Investments9.8 M10.3 M42.1 M
Slightly volatile
Total Liabilities14.6 M18 M13.8 M
Very volatile
Intangible Assets10.4 M13.2 M11.5 M
Slightly volatile
Common Stock181.2 K286 K161.5 K
Slightly volatile
Property Plant Equipment4.7 M3.7 M5.7 M
Slightly volatile
Property Plant And Equipment Net4.5 M3.4 M5.7 M
Slightly volatile
Current Deferred Revenue987.3 K750 K1.7 M
Slightly volatile
Non Current Assets Total13.2 M16.6 M11.5 M
Slightly volatile
Non Currrent Assets Other28.4 K28 K28.3 K
Very volatile
Cash And Short Term Investments55.2 M31.1 M66.2 M
Slightly volatile
Net Receivables1.5 M2.4 M1.8 M
Pretty Stable
Common Stock Total Equity157.2 K230 K151.8 K
Slightly volatile
Liabilities And Stockholders Equity66.8 M51.1 M79.9 M
Slightly volatile
Non Current Liabilities Total6.5 M11 M6.1 M
Slightly volatile
Other Stockholder Equity225.1 M269.4 M190.7 M
Slightly volatile
Property Plant And Equipment Gross27.3 M26 M8.8 M
Slightly volatile
Total Current Assets57.2 M34.5 M68.6 M
Slightly volatile
Short Term Debt1.7 M853 K2.1 M
Slightly volatile
Net Tangible Assets11.8 M12.4 M71 M
Slightly volatile
Long Term Investments341.2 K343.8 K400.5 K
Slightly volatile
Deferred Long Term Liabilities76.1 K80.1 K226.1 K
Slightly volatile
Short and Long Term Debt2.5 M2.6 M3.2 M
Slightly volatile
Capital Surpluse207.6 M236.8 M193.8 M
Slightly volatile
Non Current Liabilities Other3.7 M4.2 M3.5 M
Slightly volatile
Net Invested Capital37.7 M22.4 M56.9 M
Slightly volatile
Net Working Capital35.8 M27.5 M55.1 M
Slightly volatile
Capital Stock227.2 K286 K173.5 K
Slightly volatile
Short and Long Term Debt Total6.9 M11.5 M4.3 M
Slightly volatile
Long Term Debt Total1.7 M1.9 MM
Slightly volatile
Capital Lease Obligations1.8 M1.1 M2.6 M
Slightly volatile
Long Term Debt11.3 M10.4 M10.2 M
Slightly volatile

Evogene Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.8 M2.6 M2.5 M
Slightly volatile
Interest Expense162.4 K171 K1.2 M
Slightly volatile
Selling General Administrative5.2 M8.7 M4.7 M
Slightly volatile
Total RevenueM5.6 M7.9 M
Slightly volatile
Gross Profit2.1 M1.4 M2.9 M
Slightly volatile
Other Operating Expenses28.6 M32 M25.7 M
Slightly volatile
Research Development18 M18.1 M15.8 M
Slightly volatile
Cost Of Revenue3.9 M4.2 MM
Slightly volatile
Total Operating Expenses23.3 M27.8 M20.6 M
Slightly volatile
Interest Income1.1 M631 K1.3 M
Pretty Stable
Minority Interest3.7 M2.2 M2.3 M
Slightly volatile
Tax Provision15.2 K16 K32.2 K
Pretty Stable
Reconciled Depreciation2.7 M2.6 M2.3 M
Slightly volatile
Selling And Marketing Expenses1.7 MM866.5 K
Slightly volatile

Evogene Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based CompensationM1.9 M2.4 M
Pretty Stable
Begin Period Cash Flow25.9 M29 M22.8 M
Pretty Stable
Depreciation2.5 M2.6 M2.2 M
Slightly volatile
Capital Expenditures1.2 M785 K1.7 M
Slightly volatile
Total Cash From Financing Activities12.2 M18.2 M15.7 M
Pretty Stable
End Period Cash Flow26.8 M20.8 M23.4 M
Pretty Stable
Sale Purchase Of Stock10.7 MM25.5 M
Slightly volatile
Issuance Of Capital Stock10.7 M8.4 M11.2 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio63.4766.81443.2 K
Very volatile
PTB Ratio29.731.2647201
Very volatile
Days Sales Outstanding21.9523.1037178
Slightly volatile
Book Value Per Share0.60.62792.6161
Slightly volatile
Stock Based Compensation To Revenue0.320.33280.8954
Slightly volatile
Capex To Depreciation0.290.30050.858
Slightly volatile
PB Ratio29.731.2647201
Very volatile
EV To Sales61.9165.17153.2 K
Very volatile
Payables Turnover0.90.94793.1531
Slightly volatile
Sales General And Administrative To Revenue1.531.07591.9858
Slightly volatile
Research And Ddevelopement To Revenue6.563.68397.5754
Slightly volatile
Capex To Revenue0.130.13920.3537
Slightly volatile
Cash Per Share0.650.67992.6455
Slightly volatile
Days Payables Outstanding260385285
Slightly volatile
Income Quality1.030.83141.1002
Slightly volatile
Intangibles To Total Assets0.140.25770.1676
Slightly volatile
Net Debt To EBITDA0.380.39845.2332
Slightly volatile
Current Ratio4.724.96399.8798
Slightly volatile
Tangible Book Value Per Share0.320.33962.4467
Slightly volatile
Receivables Turnover16.5915.79836.5798
Very volatile
Graham Number1.671.76145.082
Pretty Stable
Shareholders Equity Per Share0.250.26382.4895
Slightly volatile
Debt To Equity0.490.86020.4039
Slightly volatile
Capex Per Share0.01630.01720.0737
Slightly volatile
Graham Net Net0.190.1961.8888
Slightly volatile
Revenue Per Share0.120.12350.3599
Slightly volatile
Interest Debt Per Share0.240.22950.0885
Slightly volatile
Debt To Assets0.150.20290.1797
Pretty Stable
Price Book Value Ratio29.731.2647201
Very volatile
Days Of Payables Outstanding260385285
Slightly volatile
Company Equity Multiplier4.454.23971.7203
Slightly volatile
Long Term Debt To Capitalization0.290.46240.2806
Slightly volatile
Total Debt To Capitalization0.290.46240.2806
Slightly volatile
Debt Equity Ratio0.490.86020.4039
Slightly volatile
Quick Ratio4.714.952911.3299
Slightly volatile
Net Income Per E B T1.10.91891.0081
Pretty Stable
Cash Ratio2.822.99143.3464
Very volatile
Days Of Sales Outstanding21.9523.1037178
Slightly volatile
Price To Book Ratio29.731.2647201
Very volatile
Fixed Asset Turnover1.171.64191.2318
Slightly volatile
Debt Ratio0.150.20290.1797
Pretty Stable
Price Sales Ratio63.4766.81443.2 K
Very volatile
Asset Turnover0.08460.11040.1023
Slightly volatile
Gross Profit Margin0.740.70.3926
Slightly volatile
Price Fair Value29.731.2647201
Very volatile

Evogene Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap358 M376.8 M15.4 B
Very volatile
Enterprise Value349.2 M367.6 M15.4 B
Very volatile

Evogene Fundamental Market Drivers

Cash And Short Term Investments31.1 M

Evogene Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
16th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Evogene Financial Statements

Evogene investors utilize fundamental indicators, such as revenue or net income, to predict how Evogene Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue750 K987.3 K
Total Revenue5.6 MM
Cost Of Revenue4.2 M3.9 M
Stock Based Compensation To Revenue 0.33  0.32 
Sales General And Administrative To Revenue 1.08  1.53 
Research And Ddevelopement To Revenue 3.68  6.56 
Capex To Revenue 0.14  0.13 
Revenue Per Share 0.12  0.12 
Ebit Per Revenue(4.70)(4.94)

Pair Trading with Evogene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.

Moving together with Evogene Stock

  0.82ME 23Andme HoldingPairCorr
  0.89VALN Valneva SE ADRPairCorr
  0.77JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr

Moving against Evogene Stock

  0.63MDGL Madrigal PharmaceuticalsPairCorr
  0.5RNXT RenovoRxPairCorr
  0.45NXGLW NexGel WarrantPairCorr
  0.4KZR Kezar Life SciencesPairCorr
  0.35MLYS Mineralys Therapeutics,PairCorr
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:
Check out the analysis of Evogene Correlation against competitors.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.46)
Revenue Per Share
1.881
Quarterly Revenue Growth
0.398
Return On Assets
(0.28)
Return On Equity
(0.82)
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.